Erratum: MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. miRNA-338-3p inhibits the migration, invasion and proliferation of human lung adenocarcinoma cells by targeting MAP3K2.Aging · 2022
   Article
2. Upregulation of XIAP promotes lung adenocarcinoma brain metastasis by modulating ceRNA network.Frontiers in oncology · 2022
   Article

Corrections and comments

• Erratum for
  MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.2017

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract